LONDON, May 12, 2025 /PRNewswire/ -- Curaleaf International, part of Curaleaf Holdings, Inc. (TSX: CURA) in collaboration with Jupiter Research LLC, a subsidiary of TILT Holdings Inc. ("TILT") (Cboe CA: TILT) (OTCPK: TLLTF), has secured regulatory approval for the first handheld liquid inhalation device designed for precise medical cannabis administration. This EU medical device certification (Regulation (EU) 2017/745) paves the way for improved patient options and a new era of innovation in medical cannabis delivery.

The liquid inhalation device is now certified as a Class IIa medical device, meeting rigorous European regulatory standards. The device includes a magnetic snap-in cartridge and a rechargeable power supply, engineered to provide a consistent and controlled cannabinoid delivery. A comprehensive technical file and full EU Declaration of Conformity were assessed and approved by a recognised EU Notified Body, validating the device's quality, safety, and clinical robustness.

EU certification supports deployment in multiple global markets and once commercialised, will enable healthcare professionals to recommend the device offered by Curaleaf International in countries including European countries, the UK, Canada, and regions across Australasia.

Boris Jordan, Chairman and CEO of Curaleaf, commented on this achievement:
"Achieving EU medical certification is more than a regulatory milestone--it's a signal that medical cannabis innovation is moving into the mainstream of global healthcare. We're proud to offer a device that meets the highest standards of safety and quality, and we look forward to supporting patients and healthcare providers across Europe and beyond with a new, accurate and discrete option for treatment."

Echoing this sentiment, TILT's Chief Executive Officer Tim Conder, added:
"Partnering with Curaleaf International on this project has been a natural extension of our long-standing partnership in the US. By delivering industry-leading, user-friendly solutions, our collaboration exemplifies how technology can revolutionise healthcare. Achieving EU medical certification on IP developed by our subsidiary Jupiter Research, validates the robustness of our engineering and R&D functions and sets a new benchmark for the industry."

This development reinforces Curaleaf International's role at the forefront of advancing access to legal, high-quality cannabis treatments across Europe and other international markets.

About Curaleaf International
Curaleaf International is shaping the future of cannabis through its commitment to research and product excellence. Powered by a strong presence at all stages of the supply chain, its unique distribution network throughout Europe, Canada and Australasia brings together pioneering research with cutting-edge cultivation, extraction, and production. Amidst a rapid growth trajectory, the emphasis on quality and expertise aims to ensure the delivery of safe and legal cannabis.

Curaleaf International's network includes a clinic, pharmacy, and laboratory in the UK; cultivation and EU-GMP processing facilities in Portugal; an EU-GMP processing, quality assurance and research site in Spain; Four20 Pharma wholesaler and distributor in Germany; a Polish wholesaler and clinic; and the EU-GMP producer Northern Green Canada.

Curaleaf International is part of Curaleaf Holdings, Inc., a leading international producer and distributor of consumer cannabis products.

About TILT and Jupiter Research
TILT Holdings manages a diverse portfolio of companies in the cannabis industry, encompassing technology, hardware, cultivation, and production. Its core business, Jupiter Research LLC, is a wholly owned subsidiary and a global distribution leader in the vaporization segment. Jupiter is dedicated to hardware design, research, development, and distribution to support cannabis brands and retailers across the United States, Canada, South America, and the European Union. Additionally, TILT is a multi-state operator, with cultivation and production facilities in three states under the Commonwealth Alternative Care and Standard Farms brands. For more information, visit www.tiltholdings.com.

Media Contact:

Curaleaf International:
Beth Sweet-Escott
Head of Communications, Curaleaf International
media@curaleafint.com

TILT:
Lynn Ricci
VP of Investor Relations & Corporate Communications, TILT Holdings Inc.
lricci@tiltholdings.com

Logo - https://mma.prnewswire.com/media/2538456/Curaleaf_International_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/curaleaf-international-in-partnership-with-jupiter-research-secures-eu-medical-device-certification-for-europes-first-handheld-liquid-inhalation-device-302451701.html

Images

Tags

More Like This

Curaleaf International Launches a Range of Medical Cannabis Products in Australia

Tilray Medical Receives Approval for First Medical Cannabis Extract in Portugal

Curaleaf Completes Acquisition of Northern Green Canada

Tilray Medical Granted Approval to Introduce Third Medical Cannabis Product in Portugal

Curaleaf to Acquire Northern Green Canada to Bolster European Flower Supply

Curaleaf Announces Fulfilment of TSX Listing Conditions and Date of Commencement of Trading on the TSX

Curaleaf Report: Online and unregulated cannabis poses serious health risks with mould, lead, and synthetic cannabinoids detected

Tilray Medical Wins Tender to Supply Luxembourg with Medical Cannabis